Overview / Abstract: |
The past two decades have seen the development of numerous new targeted therapies for multiple myeloma (MM). Included among these are antibody–drug conjugates (ADCs), which have shown significant promise in improving patient prognoses but are associated with unique adverse events (AEs). In particular, ADCs containing monomethyl auristatin F (MMAF) have been linked to increased incidence of corneal epithelial changes. With the FDA’s 2020 approval of belantamab mafodotin (the first ADC indicated for MM treatment)—and its accompanying risk evaluation and mitigation strategy (REMS)—the issues of managing potential ocular toxicity and conducting routine ophthalmologic monitoring throughout the course of treatment become paramount. This monograph has been developed to provide ophthalmologists and optometrists involved in the care of MM patients receiving belantamab mafodotin guidance on the recommended management strategies for immunotherapy-associated ocular AEs. |
Expiration |
Aug 10, 2022 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Optometry / Ophthalmology CE, Physician CME, Physician Assistant CME |
Format |
Monograph, Online |
Credits / Hours |
0.75 |
Accreditation |
ACCME, COPE |
Presenters / Authors / Faculty |
Ajay K. Nooka, MD, MPH, FACP Praneetha Thulasi, MD |
Activity Specialities / Related Topics |
Oncology / Cancer / Radiation Therapy, Hematology |
Sponsors / Supporters / Grant Providers |
This educational activity is supported by an educational grant from GlaxoSmithKline. |
Keywords / Search Terms |
RedMedEd, Monograph, Ocular toxicities, antibody-drug conjugates, ADC, multiple myeloma, COPE, belantamab mafodotin, Free CE CME, ophthalmology, optometry, keratopathy, monomethyl auristatin F, MMAF, microcyst-like epithelial changes, MECs, best-corrected visual acuity, BCVA, corneal examination, ocular screening |